There are multiple chapters near you. Select your preferred chapter.

For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ ...

Lupus can do irreversible harm to a person's organs, damaging the lungs, kidneys, heart, liver and other vital organs through ...

The Lupus Foundation of America is a nonprofit whose mission is to "improve the quality of life for all people affected by ...

In the United States, SLE treatment trends between 2007 and 2023 show a continued reliance on glucocorticoids, despite advances in steroid-sparing agents.

EXCLUSIVE: Loose Women star Kelly Bryan opened up about her ongoing battle with lupus - a condition she has been living with ...

However, a newer lupus drug, anifrolumab (brand name Saphnelo), has shown promising results in reducing organ damage, ...

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...

Roche’s Gazyva/Gazyvaro (obinutuzumab) has demonstrated superiority over standard therapy in patients with active lupus ...

Children with lupus nephritis who receive belimumab achieve treatment targets faster, and can taper glucocorticoids earlier, than those using standard immunotherapy, according to data published in ...

Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.